Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 5/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23399729 | 0.81 | CYP1A2 (0.41) | PDE1APDE1BPDE1CMAPTALDH1A1 | |
| SCHEMBL29406288 | 0.80 | MAPT (0.43) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL13974491 | 0.80 | MAPT (0.43) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL22659757 | 0.79 | HSD11B1 (0.42) | CYP1A2CYP2C19CYP3A4TLR8ALOX5AP | |
| SCHEMBL17619611 | 0.78 | SMN1; SMN2 (0.50) | PDE1APDE1BPDE1CMAPTALDH1A1 | |
| SCHEMBL10103967 | 0.73 | SMN1; SMN2 (0.58) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2683566 | 0.70 | KDR (0.48) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10103716 | 0.70 | RET (0.46) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4664677 | 0.70 | MAPT (0.47) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL691317 | 0.69 | POLB (0.44) | PDE1APDE1BPDE1CMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | PDE1A 3767/4885PDE1B 3896/4885PDE1C 4399/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | PDE1A 3767/4885PDE1B 3896/4885PDE1C 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.